HMR Files For Tavanic In The UK

27 January 1997

- Hoechst Marion Roussel has filed for marketing clearance of itsantibiotic Tavanic (levofloxacin) with the UK Medicines Control Agency. Approval in the UK is expected by September of this year, and in the European Union by April 1998. The antibiotic, which is from the quinolone class and has been tested in a range of indications including sepsis, intra-abdominal infections and sinusitis, is particularly effective in the treatment of respiratory tract diseases, says the company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight